tiprankstipranks
Connect Biopharma sees cash runway into 2025
The Fly

Connect Biopharma sees cash runway into 2025

Connect Biopharma provided a business update for its operations and clinical trial development programs. The Company is actively seeking potential global and regional partners who would be able to provide additional experience and infrastructure to support the next phase of clinical development for CBP-201, including providing potential input into the clinical trial designs that furthers Connect Biopharma’s goal of delivering a differentiated therapeutic program with improved efficacy and dosing convenience. Partnership efforts focus on CBP-201’s potential not only in AD, but also in other disease indications with significant unmet need including asthma, which is in Phase 2, and for which the Company expects to report topline results during the second half of 2023. CBP-201 Pivotal AD trial in China: In October 2022, Connect Biopharma announced positive topline Stage 1 data on the primary analysis population of 255 patients and is currently conducting the 36-week Stage 2 period, which importantly, includes a potentially differentiated once a month dose regimen. The Company expects to have pre-New Drug Application interactions with the Center for Drug Evaluation of China’s National Medical Products Administration in the first quarter of 2023 to discuss the Company’s CBP-201 data package for a potential NDA filing as early as 2024 and potential approval in China as early as 2025. CBP-307 Phase 2 trial in moderate-to-severe Ulcerative Colitis: The Company also anticipates completing the global Phase 2 maintenance phase for CBP-307 in the first half of 2023. The Company reported efficacy data in May 2022 for the 12-week induction phase of the trial showing CBP-307 0.2 mg once daily administration led to a significantly higher number of patients compared to placebo achieving clinical remission based on adapted Mayo score. The Company is actively seeking to out-license CBP-307 for future trials in UC and Crohn’s disease to capitalize on its potential to be a competitive asset and a welcome addition to the gastroenterologist’s treatment armamentarium. CBP-174 in Pruritus associated with AD: The Company previously reported results from its Phase 1 single ascending dose study for CBP-174 in pruritus associated with AD and is continuing to evaluate next steps for clinical development. Anticipated 2023 Milestones: CBP-201 Pivotal China trial in AD: On track to engage with the CDE in the first quarter of 2023. Anticipate 36-week Stage 2 completion in the second half of 2023; CBP-201 in Asthma: Anticipate completing enrollment for the global Phase 2 trial in the first half of 2023 and reporting top-line results in the second half of 2023; CBP-307 in UC: Anticipate completing Phase 2 maintenance phase and reporting the results in the first half of 2023

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on CNTB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles